Until now, immunosuppressive therapy, mainly glucocorticoids, is recommended for patients with persistent proteinuria greater than 1 g/24 h despite optimized and tolerated angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin AT(1)-receptor blockers (ARBs) administration including the KDIGO 2021 guidelines for the management of glomerular diseases regarding the IgAN treatment10–12,14–16,28. This evidence concerns the gene ACE and glomerular disorder.